Medtronic gets FDA approval for Brainsense device

In Parkinson’s fight, Medtronic’s first-in-the-world adaptive therapy feature wins FDA approval
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.
US FDA approves Medtronic's medical device for Parkinson's disease
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.
Medtronic gets FDA approval for Brainsense device in Parkinson's patients
Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment for people with Parkinson's disease, a major milestone for the technology.
Medtronic gains FDA OK for self-adjusting DBS system for Parkinson’s
Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for people with Parkinson’s disease, a movement disorder of the nervous system.
FDA approves Medtronic’s brain stimulation system for Parkinson’s
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
Medtronic wins first FDA nod for adaptive DBS for Parkinson’s
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
FDA approves Medtronic’s adaptive deep-brain stimulator for Parkinson’s disease
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation ap | The company said its U.
FDA approves Medtronic device for Parkinson's treatment
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain activity,
FDA approves Medtronic’s adaptive technology for Parkinson’s
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.
Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...
Medtronic evaluating manufacturing footprint amid higher tariffs: report
Medtronic (NYSE:MDT), which has operations worldwide, is reportedly looking at adjusting its manufacturing footprint amid ...
Medical Design and Outsourcing13h
A Medtronic engineer shares lessons from the adaptive deep brain stimulation project
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Why Medtronic Stock Is Sinking Today
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
Zacks.com on MSN10h
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic
Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), ...
devdiscourse11h
Health Sector Headlines: From Tariff Talk to Drug Pricing Dynamics
The latest health news reveals Medtronic's strategic response to U.S. tariffs, WHO's concerns on West Bank violence, mystery ...
Is Medtronic Stock a Buy?
Medtronic's stock is probably not a jaw-dropping bargain at these prices, but it's an excellent business at a reasonable value. It's safe to call Medtronic a solid buy, especially if you're a ...